Evidence map›Paper›PMID 36948600›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023

Oral antiviral therapies for COVID-19 in patients with advanced chronic kidney disease or kidney failure.

Wonkyung J Cho, Destiny Harden, Daiana Moreno, James E Dinulos, Paul E Hanna, Qiyu Wang, Arthur Y Kim, Meghan E Sise

Abstract readLetter
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Frontiers in pharmacology · 2025
    Article
  3. Article
  4. Article
  5. Management of Kidney Transplant Outpatients With COVID-19: A Single Center Experience.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wonkyung J ChoMassachusetts Eye and Ear Infirmary, Boston, MA, USA.ORCID 0000-0002-0290-8667
Destiny HardenDepartment of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.
Daiana MorenoDepartment of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.
James E DinulosDepartment of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.
Paul E HannaDepartment of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.
Qiyu WangDepartment of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-4959-7437
Arthur Y KimDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Meghan E SiseDepartment of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.

Funding

Effect of Covid-19 on chronic kidney disease progressionR03DK128533 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI SISE, MEGHAN E. · 2021 to 2022
$252k
NIDDK NIH HHS R03 DK128533
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsCOVID-19Kidney Failure, ChronicRenal Insufficiency, ChronicCytidineHumansHydroxylaminesRitonavirAntiviral AgentsCytidineHydroxylaminesmolnupiravirRitonavir

Identifiers

PMID36948600
PMCPMC10387392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.